559 related articles for article (PubMed ID: 25381130)
1. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
2. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.
Pemmaraju N
Curr Hematol Malig Rep; 2017 Dec; 12(6):510-512. PubMed ID: 29064022
[No Abstract] [Full Text] [Related]
3. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm.
Philippe L; Ceroi A; Bôle-Richard E; Jenvrin A; Biichle S; Perrin S; Limat S; Bonnefoy F; Deconinck E; Saas P; Garnache-Ottou F; Angelot-Delettre F
Haematologica; 2017 Nov; 102(11):1861-1868. PubMed ID: 28798071
[TBL] [Abstract][Full Text] [Related]
5. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel AE; Woo JH; Ahn C; Pemmaraju N; Medeiros BC; Carraway HE; Frankfurt O; Forman SJ; Yang XA; Konopleva M; Garnache-Ottou F; Angelot-Delettre F; Brooks C; Szarek M; Rowinsky E
Blood; 2014 Jul; 124(3):385-92. PubMed ID: 24859366
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
7. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
8. Treatment advances in blastic plasmacytoid dendritic cell neoplasm.
Pemmaraju N
Clin Adv Hematol Oncol; 2019 Apr; 17(4):207-209. PubMed ID: 31188810
[No Abstract] [Full Text] [Related]
9. [Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic study].
Sang W; Wang CF; Cheng YF; Liu X; Li XX; Gulinar A; Li JZ; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):326-30. PubMed ID: 22883672
[TBL] [Abstract][Full Text] [Related]
10. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
11. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
12. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
13. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
[TBL] [Abstract][Full Text] [Related]
14. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
15. An unusual case of cutaneous blastic plasmacytoid dendritic cell neoplasm with concomitant B-cell lymphoproliferative disorder.
Patel JL; Shetty S; Salama ME
Am J Dermatopathol; 2011 May; 33(3):e31-6. PubMed ID: 20861710
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
[TBL] [Abstract][Full Text] [Related]
17. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
18. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications.
Jegalian AG; Buxbaum NP; Facchetti F; Raffeld M; Pittaluga S; Wayne AS; Jaffe ES
Haematologica; 2010 Nov; 95(11):1873-9. PubMed ID: 20663945
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
